C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 215/42 (2006.01) A61K 31/4025 (2006.01) A61K 31/496 (2006.01) A61K 31/5377 (2006.01) A61K 31/551 (2006.01) A61P 1/00 (2006.01) A61P 3/04 (2006.01) A61P 5/00 (2006.01) A61P 15/00 (2006.01) A61P 21/02 (2006.01) A61P 25/14 (2006.01) A61P 25/20 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) A61P 43/00 (2006.01) C07D 207/14 (2006.01) C07D 215/233 (2006.01) C07D 215/48 (2006.01) C07D 241/04 (2006.01) C07D 243/08 (2006.01) C07D 265/30 (2006.01) C07D 311/24 (2006.01) C07D 401/04 (2006
Patent
CA 2465350
Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
La présente invention concerne un composé représenté par la formule générale (I). Dans cette formule, R?2¿ est normalement un atome d'azote tertiaire éventuellement alkyle-substitué ou membre d'un noyau hétérocyclique, et R?7¿ est normalement un noyau aromatique monocyclique ou bicyclique ou un noyau hétérocyclique. Ces composés conviennent particulièrement pour le traitement de troubles psychiatriques, et notamment la dépression, l'anxiété généralisée, les troubles de l'alimentation, la démence, le trouble panique, et les troubles du sommeil. Les composés conviennent également pour le traitement de troubles gastro-intestinaux, de troubles de la régulation cardio-vasculaire, de troubles moteurs, de troubles endocriniens, des spasmes vasculaires, et de dysfonction sexuelle. Ces composés sont des antagonistes des 5HT¿1B? et 5HT¿1D?.
Chapdelaine Marc
Davenport Timothy
Haeberlein Markus
Horchler Carey
Mccauley John
Astrazeneca Ab
Mccarthy Tetrault Llp
LandOfFree
Therapeutic quinoline compounds with 5-ht-antagonistic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic quinoline compounds with 5-ht-antagonistic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic quinoline compounds with 5-ht-antagonistic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1988168